DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
The QUELIMMUNE therapy has been adopted by nationally recognized children’s medical centers in the United States. The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic ...
SeaStar Medical Holding Corporation (NASDAQ:ICU) shares are trading higher on Thursday, on continued strength after the company received FDA Breakthrough Device Designation for its cell-directed ...
Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- ...
SeaStar Medical (NASDAQ:ICU) said it has received an Approvable Letter from the FDA for its Selective Cytopheretic Device Pediatric, or SCD-PED, for use in children with acute kidney injury and sepsis ...
SeaStar Medical Holding ( ($ICU) ) has provided an announcement. On September 24, 2025, SeaStar Medical announced that the independent Data Safety ...
DENVER, COLORADO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary ...
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
Background Sudden cardiac death (SCD) is a common cause of cardiovascular mortality, often triggered by ventricular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback